{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"description":"Any documented flu infection during the 2015-2016 flu season or evidence of disease progression.","groups":[{"description":"Fluzone High dose vaccine administered at Day 0. Fluzone High dose vaccine administered as a booster after 30 days from the initial vaccine.\n\nFluzone High Dose Vaccine","id":"OG000","title":"Fluzone High Dose Vaccine Then Fluzone High Dose Booster"},{"description":"Fluzone High-Dose if age greater than or equal to 65 or Standard dose influenza vaccine if age less than 65 at day 0. Placebo administered 30 days after the initial vaccine.\n\nStandard of care/Placebo","id":"OG001","title":"Standard of Care"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"1 year","title":"Number of Participants With Treatment Failure by Primary Endpoint","type":"PRIMARY","unitOfMeasure":"Participants"}